ENGN enGene Therapeutics Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1980845 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-37.6%
TTM EPS YoY305.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-60.5%
ROA-48.8%
ROIC (approx.)-60.4%
Asset turnover—
Leverage & solvency
Liabilities / assets20.1%
Debt / equity0.00x
Current ratio10.21x
Interest coverage-44.51x
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-07-31 | 2026Q22026-04-30 | 2026Q12026-01-31 | 2025Q4*2025-10-31 | 2025Q32025-07-31 | 2025Q22025-04-30 | 2025Q12025-01-31 | 2024Q4*2024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $20.09M | $22.20M | $22.25M | $31.72M | $22.57M | $20.21M | $19.97M | $11.27M |
| SG&A expense | $13.92M | $9.77M | $8.93M | $7.76M | $7.37M | $6.92M | $6.64M | $6.18M |
| Operating income | -$34.01M | -$31.97M | -$31.18M | -$39.48M | -$29.95M | -$27.12M | -$26.61M | -$17.45M |
| Interest expense | $843,000 | $745,000 | $732,000 | $750,000 | $758,000 | $734,000 | $752,000 | $756,000 |
| Pretax income | -$32.50M | -$30.23M | -$29.75M | -$38.38M | -$28.75M | -$25.57M | -$24.60M | -$15.28M |
| Income tax | $0 | $0 | $0 | -$497,000 | $239,000 | $240,000 | $18,000 | $19,000 |
| Net income | -$32.50M | -$30.23M | -$29.75M | -$37.88M | -$28.99M | -$25.82M | -$24.62M | -$15.30M |
| EBITDA | -$33.91M | -$31.77M | -$31.00M | -$39.28M | -$29.85M | -$27.02M | -$26.51M | -$17.36M |
| EPS (basic) | -0.47 | -0.43 | 0.44 | — | -0.57 | -0.51 | 0.48 | — |
| EPS (diluted) | -0.47 | -0.43 | 0.44 | — | -0.57 | -0.51 | 0.48 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 69.73M | 69.72M | 67.26M | — | 51.10M | 51.02M | 50.98M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.02M | $29.83M | $36.61M | $50.15M | $32.62M | $57.55M | $62.35M | $173.00M |
| Short-term investments | $225.29M | $228.64M | $239.34M | $143.58M | $169.29M | $159.85M | $151.47M | $65.33M |
| Current assets | $277.90M | $270.00M | $289.22M | $201.39M | $211.31M | $227.97M | $222.32M | $247.36M |
| PP&E, net | $2.16M | $2.33M | $2.44M | $2.48M | $1.88M | $1.55M | $1.37M | $1.17M |
| Total assets | $288.32M | $307.52M | $337.11M | $221.47M | $245.55M | $266.65M | $285.93M | $311.17M |
| Current liabilities | $27.21M | $21.48M | $24.61M | $31.98M | $20.44M | $18.00M | $12.96M | $14.66M |
| Total liabilities | $58.03M | $52.36M | $55.57M | $53.76M | $44.88M | $39.36M | $35.98M | $38.56M |
| Shareholders' equity | $230.29M | $255.17M | $281.55M | $167.71M | $200.67M | $227.29M | $249.95M | $272.61M |
| Shares outstanding | 67.01M | 66.99M | 66.99M | 52.02M | 51.11M | 51.07M | 50.98M | 50.98M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.95M | -$30.50M | -$28.90M | -$24.96M | -$25.63M | -$22.95M | -$25.70M | -$19.57M |
| Capital expenditure | $0 | $98,000 | $153,000 | $437,000 | $704,000 | $45,000 | $299,000 | $238,000 |
| Free cash flow | -$18.95M | -$30.60M | -$29.06M | -$25.40M | -$26.34M | -$22.99M | -$26.00M | -$19.81M |
| Investing cash flow | $30.12M | $23.64M | -$126.30M | $40.50M | $1.38M | $17.95M | -$84.96M | -$125.27M |
| Financing cash flow | $23,000 | $74,000 | $141.66M | $1.99M | -$667,000 | $199,000 | $1,000 | $60.16M |
| Depreciation & amortization | $100,000 | $200,000 | $189,000 | $200,000 | $100,000 | $100,000 | $102,000 | $100,000 |
| Stock-based compensation | $7.81M | $4.14M | $2.80M | $2.61M | $2.58M | $2.65M | $1.81M | $1.66M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.